Log in

NASDAQ:CRDFCreative Realities Stock Price, Forecast & News

-0.49 (-7.59 %)
(As of 08/12/2020 04:00 PM ET)
Today's Range
Now: $5.97
50-Day Range
MA: $4.84
52-Week Range
Now: $5.97
Volume662,700 shs
Average Volume706,147 shs
Market Capitalization$119.21 million
P/E RatioN/A
Dividend YieldN/A
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CRDF



Sales & Book Value

Annual Sales$250,000.00
Book Value$0.94 per share


Net Income$-16,410,000.00
Net Margins-4,732.48%


Market Cap$119.21 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
-0.49 (-7.59 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRDF News and Ratings via Email

Sign-up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Creative Realities (NASDAQ:CRDF) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Creative Realities?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Creative Realities in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Creative Realities

When is Creative Realities' next earnings date?

Creative Realities is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Creative Realities

How were Creative Realities' earnings last quarter?

Creative Realities (NASDAQ:CRDF) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.27. Creative Realities had a negative net margin of 4,732.48% and a negative return on equity of 229.26%.
View Creative Realities' earnings history

What price target have analysts set for CRDF?

2 brokerages have issued 1-year price targets for Creative Realities' stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate Creative Realities' stock price to reach $14.50 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts' price targets for Creative Realities

Has Creative Realities been receiving favorable news coverage?

Press coverage about CRDF stock has been trending extremely negative on Thursday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Creative Realities earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Creative Realities

Who are some of Creative Realities' key competitors?

What other stocks do shareholders of Creative Realities own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Creative Realities investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), VIVUS (VVUS), ABB (ABB), AIM ImmunoTech (AIM), Akero Therapeutics (AKRO), Brainstorm Cell Therapeutics (BCLI), CymaBay Therapeutics (CBAY) and Ciena (CIEN).

Who are Creative Realities' key executives?

Creative Realities' management team includes the following people:
  • Dr. Thomas H. Adams, Exec. Chairman & CEO (Age 77, Pay $735.76k)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 60, Pay $597.33k)
  • Ms. Brigitte Lindsay, VP of Fin.
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Ms. Vicki Kelemen, VP of Investor Relations & Clinical Devel..

What is Creative Realities' stock symbol?

Creative Realities trades on the NASDAQ under the ticker symbol "CRDF."

How do I buy shares of Creative Realities?

Shares of CRDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Creative Realities' stock price today?

One share of CRDF stock can currently be purchased for approximately $5.97.

How big of a company is Creative Realities?

Creative Realities has a market capitalization of $119.21 million and generates $250,000.00 in revenue each year. Creative Realities employs 12 workers across the globe.

What is Creative Realities' official website?

The official website for Creative Realities is www.trovagene.com.

How can I contact Creative Realities?

Creative Realities' mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The company can be reached via phone at 858-952-7570 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.